INS and type 1 diabetes mellitus: In the United States, McQueen et al. (2011) found that, for adults with T1D, who use multiple daily insulin injections, CGM was associated with an incremental cost-effectiveness ratio (ICER)38 of approximately $45,033 [€40,917]39 per quality-adjusted life year (QALY); Huang et al. (2010) found that the ICER of CGM use was $78,943 [€72,635] per QALY; and Wan et al. (2018) established a higher ICER of $98,108 [€89,140] per QALY for lifetime use of CGM—noting that, by extending sensor use from 7 to 10 days, the ICER was reduced to $33,459 [€30,327] per QALY.